MetLife Inc. Stock: Analyst Outperform Ratings and Undervaluation Signal Potential Upside for Investors

MetLife Inc. (ISIN: US59156R1086, NYSE:MET) receives fresh 'Outperform' reinstatement from Keefe, Bruyette & Woods with an $87 target, amid analyses showing the stock undervalued by over 60% at recent levels around $70. This comes as institutional interest remains strong despite some stake adjustments.

MetLife Inc. shares have drawn fresh attention from Wall Street as Keefe, Bruyette & Woods reinstated an 'Outperform' rating with a $87.00 price target on March 26, 2026. This move underscores analyst confidence in the insurance giant's trajectory amid recent share price weakness. Investors eyeing stable dividend payers in the financial sector may find MetLife's profile compelling right now.

As of: 27.03.2026

By Elena Vargas, Senior Financial Editor at NorthStar Market Insights: MetLife stands as a cornerstone in global insurance, navigating sector dynamics with a diversified footprint that appeals to conservative North American portfolios.

Core Business and Global Reach

MetLife Inc., listed on the NYSE under ticker MET with ISIN US59156R1086, operates as a leading provider of insurance, annuities, and employee benefit programs worldwide. The company traces its roots to 1863, evolving into a multinational with significant exposure across multiple regions. Its U.S.-based Group Benefits and Retirement and Income Solutions segments contribute substantially to earnings.

These U.S. operations account for around 48% of the firm's 2024 adjusted earnings, highlighting North America's core importance. Internationally, the Asia segment, particularly Japan, drives about 25% of earnings. Latin America, with strong positions in Mexico and Chile, adds another 13%.

EMEA and MetLife Holdings round out the portfolio at roughly 4% and 10%, respectively. This diversification buffers against regional economic swings, a key strength for investors seeking resilience. MetLife's scale positions it well in a sector where size often correlates with pricing power and risk management capabilities.

Recent Analyst Sentiment and Price Targets

Keefe, Bruyette & Woods analyst Ryan Krueger reinstated the 'Outperform' rating on MetLife shares with a $87.00 target on March 26, 2026. This aligns with broader analyst optimism, as the consensus points to an average target of $91.92 from 13 analysts, ranging from $80.00 to $103.00. Such targets suggest meaningful upside from recent closing levels around $70.

Other firms have adjusted targets downward slightly but maintained positive stances: TD Cowen holds 'Buy' at $88.00, Morgan Stanley 'Overweight' at $93.00, and Wells Fargo 'Overweight' at $93.00. These updates reflect nuanced views on interest rates and economic conditions impacting insurance valuations. The Moderate Buy consensus, with two Strong Buys and eight Buys, reinforces a favorable outlook.

One valuation model estimates MetLife's intrinsic value at $193.26 per share, implying 63.6% undervaluation relative to a recent $70.39 close. Built on book value of $43.33, stable EPS of $8.78, and ROE of 15.91%, this analysis highlights potential for excess returns. Investors should note such models rely on analyst forecasts and assumptions about future equity costs.

Financial Performance and Dividend Strength

MetLife demonstrated operational resilience with Q4 results showing EPS of $2.49, surpassing estimates of $2.34. Revenue reached $52.44 billion, far exceeding expectations of $31.43 billion, up 27.6% year-over-year. Net margin stood at 4.38% and return on equity at 21.81%, signaling efficient capital use.

Analysts project full-year EPS of $9.65. The company maintains a quarterly dividend of $0.5675, paid March 10, 2026, to shareholders of record February 3, yielding about 3.2% annualized. This payout, with a market cap around $45.85 billion, P/E of 14.96, PEG of 0.63, and beta of 0.76, positions MET as a defensive pick.

Over longer horizons, shares delivered 36.7% returns over three years and 34.8% over five, despite recent YTD and one-year dips. A one-year low of $65.21 and high of $84.99 frame the trading range. These metrics appeal to income-focused North American investors prioritizing steady yields over volatility.

Institutional Ownership and Investor Relevance

Institutional ownership exceeds 94.99%, reflecting deep conviction from major players. Vanguard Group increased its stake by 12.06%, adding over 7.8 million shares to hold about 72.55 million valued at roughly $5.727 billion. Norges Bank initiated a significant position, while AQR, Amundi, and First Trust boosted holdings.

Not all moves were additive; Wealth Enhancement Advisory Services trimmed its stake by 10.3% in Q4, selling 26,772 shares but retaining 232,273 worth $18.85 million. High institutional interest validates MetLife's role in diversified portfolios. For North American investors, the U.S.-centric earnings base offers familiarity and tax advantages.

MetLife's beta of 0.76 indicates lower market sensitivity, ideal for balancing riskier assets. Amid economic uncertainty, its dividend reliability and undervaluation case make it relevant now. Pension funds and retirees particularly value this profile for long-term income generation.

Risks and Open Questions for Investors

Interest rate fluctuations pose a primary risk, as they influence investment income and liability valuations in insurance. Recent analyst target trims reflect caution on this front. Share price weakness, with a 6.4% monthly drop and 12.4% YTD decline as of recent data, underscores market pressures.

Regulatory changes, especially in international markets like Asia and Latin America, could impact earnings growth. Currency volatility adds another layer for a global operator. MetLife's recent appointment of Jordan Canter as Head of Federal Government Affairs effective April 20 signals proactive U.S. policy engagement.

What to watch next: Upcoming earnings, rate decisions, and dividend declarations. Track analyst updates and institutional flows for sentiment shifts. North American investors should monitor U.S. segment performance, given its outsized earnings role.

Strategic Outlook and Competitive Position

MetLife competes in a consolidated industry against peers like Prudential and Lincoln National, leveraging its scale for cost efficiencies. Leadership in group benefits and annuities bolsters its moat. The firm's focus on retirement solutions aligns with aging demographics in key markets.

Diversification across products—life insurance, annuities, auto & home—mitigates single-line risks. Asia's growth potential, tied to rising middle classes, offers upside. Latin American dominance provides emerging market exposure with established footholds.

For conservative investors, MetLife's track record of beating EPS estimates and revenue growth stands out. The low PEG ratio suggests growth at a reasonable price. Monitoring macroeconomic indicators like inflation and employment will inform entry points.

Overall, the combination of analyst support, undervaluation signals, and robust fundamentals positions MetLife shares as a watchlist candidate. Its dividend yield and institutional backing enhance appeal amid sector rotations toward value.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.